The Atlantic Health Cancer Consortium Community Oncology Research Program (AHCC CORP)
The Atlantic Health Cancer Consortium Community Oncology Research Program (AHCC CORP)
批准号:
10668415
负责人:
Eric Whitman
金额:
$92.49万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-08-27 至 2025-07-31
关键词:
AdultAgeAreaCancer ControlCancer Control ResearchCatchment AreaChildhoodClinicalClinical TrialsCollaborationsCollectionCommunitiesCommunity Clinical Oncology ProgramCountyData CollectionDevelopmentEnrollmentGenomicsGeographyGoalsHealthHealth Services AccessibilityHealthcare SystemsIncidenceInfrastructureLanguageLeadershipMalignant Childhood NeoplasmMalignant NeoplasmsModalityNational Clinical Trials NetworkNatural Language ProcessingNew JerseyOncologistOncologyOutcomeParticipantPatient-Focused OutcomesPatientsPediatric HospitalsPersonsPhysiciansPopulationPopulation HeterogeneityProceduresProcessProtocols documentationProviderQuality of CareResearchResearch PersonnelScienceScientific Advances and AccomplishmentsSiteSpecimenUnderrepresented Populationsbasecancer carecancer health disparitycancer preventioncare deliverychatbotclinical implementationclinically significantcommunity engagementcommunity settingdata submissiondemographicsdisparity reductionexperienceimaging studyimprovedinnovationinter-institutionalmedical specialistmedical specialtiesmembermentoring communitymolecular targeted therapiesorganizational structureoutcome disparitiespatient populationprecision medicineprevention clinical trialprogramsrecruitresearch studyretention ratescreeningsocial mediatumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Atlantic Health Cancer Consortium Community Oncology Research Program (AHCC-CORP) is the first
NCORP Community Site within the state of New Jersey and combines the collective strengths of world-class
healthcare systems with community oncology care delivery. AHCC-CORP covers a geographically and
demographically diverse area representing 73% of New Jersey’s population. AHCC-CORP expands the
NCORP network by 6.5M people; with a higher cancer incidence rate than the US as a whole (477.5 vs 441.2
cases per 100,000). Regions of AHCC-CORP are even further elevated.
Specific Aims include: 1) Increase adult and pediatric accruals to NCI cancer prevention, control,
screening, and care delivery research studies, as well as treatment and imaging studies conducted by
the National Clinical Trials Network (NCTN) and biospecimen collection. This will be accomplished by
creating a unique and unprecedented cancer care consortium in New Jersey. The Consortium has experienced
cancer investigators in adult and pediatric cancers across multiple sites, including three children's hospitals.
Separately, Consortium sites annually accrue an average of 130 participants to NCORP Research Bases, but
with the leadership and infrastructure support of AHCC-CORP, affiliates are now poised to even further
increase accruals. 2) Enhance community engagement in cancer control and prevention clinical trials
and Cancer Care Delivery Research (CCDR) conducted by NCORP in the AHCC-CORP catchment area.
Engagement will be enhanced through innovative approaches that effectively engage physicians, patients, and
the community. Developments notably include video vignettes for social media dissemination and interactive
chatbot capabilities powered by natural language processing, allowing recruitment/retention strategies in
multiple languages in support of cancer disparities integration. Additionally, AHCC-CORP has a clearly-defined
process for prioritizing NCORP and NCTN trials for activation, and procedures in support of successful study
accrual and data collection across sites. AHCC-CORP will also support and mentor community oncologists and
other medical specialists in central and northern New Jersey, furthering capabilities in cancer care delivery
research. 3) Contribute to the development and implementation of clinically significant studies that
incorporate the unique research needs of the diverse population within the AHCC NCORP catchment
area, leveraging the expertise of established oncology specialty physicians and other providers within
our affiliate network. The established clinical and research expertise, across multiple tumor types and
research modalities, of AHCC-CORP physicians and other providers will be leveraged to support NCORP
overarching programmatic goals through active involvement in Research Bases and other NCORP-wide
research leadership committees.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Atlantic Health Cancer Consortium Community Oncology Research Program (AHCC CORP)
-
批准号:10228675
-
项目类别:
-
资助金额:$87.56万
-
财政年份:2019
-
负责人:Eric Whitman
-
依托单位:
The Atlantic Health Cancer Consortium Community Oncology Research Program (AHCC CORP)
-
批准号:10453746
-
项目类别:
-
资助金额:$87.07万
-
财政年份:2019
-
负责人:Eric Whitman
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: